La cascade des MAP kinases : traitements ciblés en cancérologie cutanée.

[fr] Résumé : Les «Mitogen-Activated Protein Kinases» (MAPK) forment un ensemble coordonné de protéines cellulaires impliquées dans la prolifération, la différenciation, la migration et l’apoptose des cellules. Elles sont particulièrement activées, par certaines cytokines, hormones, le stress environnemental, ainsi que dans des cancers cutanés. Des agents pharmacologiques ciblés contre la cascade MAPK révolutionnent actuellement la cancérologie cutanée, du moins dans une phase transitoire du processus métastatique. Des traitements combinés sont susceptibles d’améliorer la survie médiane.

Disciplines :

Dermatology

Author, co-author :

PIERARD, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Franchimont, Claudine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

LEONARD, Boris ; Centre Hospitalier Universitaire de Liège - CHU > Anatomie pathologique

Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Language :

French

Title :

La cascade des MAP kinases : traitements ciblés en cancérologie cutanée.

Alternative titles :

[en] The MAP kinase cascade. A key target for treatments in skin cancerology.

Publication date :

December 2013

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

650-654

Peer reviewed :

Peer reviewed

Available on ORBi :

since 11 January 2014

Statistics

Number of views

75 (8 by ULiège)

Number of downloads

1310 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Segar R, Krebs EG. - The MAPK signalling cascade. FASEB J, 1995, 9, 726-798.
Hironobu I. - P38 MAPK inhibitors in dermatology. Exp Rev Dermatol, 2007, 2, 403-407.
Piérard GE, Piérard-Franchimont C, Hermanns-Lê T, et al. - Le mélanome cutané: une seule maladie? Rev Med Liège, 2012, 67, 458-460.
Piérard-Franchimont C, Piérard GE. - Le mélanome métastatique : un vent d'espoir porté par l'ipilimumab et le vemurafenib. Rev Med Liège, 2012, 67, 64-68.
Piérard GE, Piérard-Franchimont C, Hermanns-Lê T, et al. - Cutaneous melanocytomas : a conceptual cluster of atypical and indolent melanocytic neoplasms. Expert Res Dermatol, sous presse.
Piérard GE. - Cell proliferation in malignant melanoma : relationship with neoplastic progression. Int Scholar Res Network Dermatol, 2012, 828146, 2012.
Raman M, Chen W, Cobb MH. - Differential regulation and properties of MAPKs. Oncogene, 2007, 26, 3100-3112.
Cohen C, Zavala-Pompa A, Sequeira JH, et al. - Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res, 2002, 8, 3728-3733.
Davies H, Bignell GR, Cox C, et al. - Mutations of the BRAF gene in human cancer. Nature, 2002, 417, 949-954.
Omholt K, Karsberg S, Platz A, et al. - Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res, 2002, 8, 3468-3474.
Cully M, You H, Levine AJ, et al. - Beyond PTEN mutations: the P13K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer, 2006, 6, 184-192.
Robertson GP. - Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev, 2005, 24, 273-285.
Stahl JM, Sharma A, Cheung M, et al. - Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res, 2004, 64, 7002-7010.
Piérard GE, Aubin F, Humbert P. - Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma? Dermatol Res Pract, 2012, 182157.
Dalle S, Poulalhon N, Thomas L. - Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 365, 1448-1449.
Hodis E, Watson IR, Kryukov GV, et al. - A landscape of driver mutations in melanoma. Cell, 2012, 150, 251-263.
Reginster MA, Piérard-Franchimont C, Piérard GE, et al. - Molecular dermatopathology in malignant melanoma. Dermatol Res Pract, 2012, 684032.
Krauthammer M, Kong Y, Ha BH, et al. - Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet, 2012, 44, 1006-1014.
Gembarska A, Luciani F, Fedele C, et al. - MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012, Epub Jul 22.
Long GV, Menzies AM, Nagrial AM, et al. - Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol, 2011, 29, 1239-1246.
Moreau S, Saiag P, Aegerter P, et al. - Prognostic value of BRAF (V600) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol, 2012, 19, 4314-4321.
Menzies AM, Haydu LE, Visintin L, et al. - Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res, 2012, 18, 3242-3249.
Colombino M, Capone M, Lissia A, et al. - BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol, 2012, 30, 2522-2529.
Cipponi A, Wieers G, van Baren N, et al. - Tumor-infiltrating lymphocytes : apparently good for melanoma patients. But why? Cancer Immunol Immunother, 2011, 60, 1153-1160.
Monzon JG, Dancey J. - Targeted agents for the treatment of metastatic melanoma. Onco Targets Ther, 2012, 5, 31-46.
Weeraratna AT. - RAF around the edges- the paradox of BRAF inhibitors. N Engl J Med, 2012, 366, 271-273.
Chapman PB, Hauschild A, Robert C, et al. - Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 364, 2507-2516.
Sosman JA, Kim KB, Schuchter L, et al. - Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med, 2012, 366, 707-714.
Hauschild A, Grob JJ, Demidov LV, et al. - Dabrafenib in BRAF-mutated metastatic melanoma : a multicentre, open-label, phase 3 randomized controlled trial. Lancet, 2012, 380, 358-365.
Piérard GE, Piérard-Franchimont C, Delvenne P. - Malignant melanoma and its stromal nonimmune microecosystem. J Oncol, 2012, 2012, 584219.
Straussman R, Morikawa T, Shee K, et al. - Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487, 50à-504.
Wilson TR, Fridlyand J, Yan Y, et al. - Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012, 487, 505-509.
Robert C, Arnault JP, Mateus C. - RAF inhibition and induction of cutaneous squamous cell carcinoma. Cur Opin Oncol, 2011, 23, 177-182.
Su F, Viros A, Milagre C, et al. - RAS mutations in cutaneous squamous cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med, 2012, 366, 207-215.
Dalle S. - Quoi de neuf en cancérologie? Ann Dermatol, 2012, 139, S217-S222.
Zimmer L, Hillen U, Livingstone E, et al. - Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol, 2012, 30, 2375-2383.
Flaherty KT, Robert C, Hersey P, et al. - Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med, 2012, 367, 107-114.
Weber JS, Flaherty KT, Infante JR, et al. - Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naïve metastatic melanoma. J Clin Oncol Proc Am Soc Clin Oncol, 2012, 30, Abstract 8510.
Hodi FS, O'Day SJ, McDermott DF, et al. - Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010, 363, 711-723.
Robert C, Thomas L, Bondarenko I, et al. - Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 2011, 364, 2517-2526.
Jang S, Atkins MB. - Which drug, and when, for patients with BRAF-mutant melanoma ? Lancel Oncol, 2013, 14, e60-69.